Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon issues stock options for 275,500 shares as inducement awards to two new non-executive employees, vesting over four years.

Rhea-AI Summary

Annexon (ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

The awards were approved on September 12, 2026, and granted on September 15, 2026. In total, the employees received options to purchase 275,500 shares of Annexon common stock. The options have a 10-year term and an exercise price of $3.92 per share, equal to the closing price of Annexon common stock on the grant date. Vesting occurs over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.

News Explained

These awards are options to purchase 275,500 shares, rather than a stated immediate transfer of those shares; any purchase is conditional on exercise and the disclosed vesting requirements.

Key Figures

Shares under options: 275,500 shares Exercise price: $3.92 per share Option term: 10 years +2 more

Shares under options

275,500 shares

Two new non-executive employees

Exercise price

$3.92 per share

Equal to the September 15 closing price

Option term

10 years

Employee inducement options

Vesting period

4 years

25% vests on the first anniversary, with monthly vesting thereafter

Initial vesting

25%

Shares vesting on the first anniversary of the grant date

Historical Context

1 past event · Latest: Aug 17

1 event

1. Aug 17

   Employee inducement grants

   24h Move

   +2.9%

   Options granted to three new employees under the same inducement award plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), exercise price, vesting

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"an exercise price per share equal to $3.92"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vest over 4 years, with 25% of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 275,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $3.92, which was the closing price of Annexon’s common stock on September 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do the new Annexon inducement stock options vest over time?

The options vest over four years. 25% of the shares underlying each option vest on the first anniversary of the grant date. The remaining 75% vest in equal monthly installments of 1/48th of the total shares over the following three years, subject to each employee’s continued service through the applicable vesting dates.

What are the key terms of the inducement stock options granted by Annexon?

The two new non-executive employees received options to purchase an aggregate of 275,500 shares of Annexon common stock. The options have a 10-year term and an exercise price of $3.92 per share, which was the closing price of Annexon’s common stock on September 15, 2026, the grant date.